Mastocytosis. Photo by Doc James via Wikimedia Commons Recent findings show treatment with the selective KIT D816V inhibitor avapritinib for indolent systemic mastocytosis (ISM) improved dermatologic symptoms, decreased skin lesion size, normalized skin lesion colour, and reduced skin mast cell burden. The study was published in the Journal of the American Academy of Dermatology . In a press release , the study’s senior author, Karin Hartmann, MD, said that her mastocytosis p